Cargando…

Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging

The tropomyosin receptor kinases family (TrkA, TrkB, and TrkC) supports neuronal growth, survival, and differentiation during development, adult life, and aging. TrkA/B/C downregulation is a prominent hallmark of various neurological disorders including Alzheimer’s disease (AD). Abnormally expressed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schirrmacher, Ralf, Bailey, Justin J., Mossine, Andrew V., Scott, Peter J. H., Kaiser, Lena, Bartenstein, Peter, Lindner, Simon, Kaplan, David R., Kostikov, Alexey, Fricker, Gert, Mahringer, Anne, Rosa-Neto, Pedro, Schirrmacher, Esther, Wängler, Carmen, Wängler, Björn, Thiel, Alexander, Soucy, Jean-Paul, Bernard-Gauthier, Vadim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469173/ https://www.ncbi.nlm.nih.gov/pubmed/30609832 http://dx.doi.org/10.3390/ph12010007

Ejemplares similares

(18)F-Labeled Silicon-Based Fluoride Acceptors: Potential Opportunities for Novel Positron Emitting Radiopharmaceuticals
por: Bernard-Gauthier, Vadim, et al.
Publicado: (2014)

Toward the Development of GE11-Based Radioligands for Imaging of Epidermal Growth Factor Receptor-Positive Tumors
por: Judmann, Benedikt, et al.
Publicado: (2022)

Dosimetry of [(18)F]TRACK, the first PET tracer for imaging of TrkB/C receptors in humans
por: Thiel, Alexander, et al.
Publicado: (2023)

Design, Synthesis, In Vitro and In Vivo Evaluation of Heterobivalent SiFAlin-Modified Peptidic Radioligands Targeting Both Integrin α(v)β(3) and the MC1 Receptor—Suitable for the Specific Visualization of Melanomas?
por: Cheng, Xia, et al.
Publicado: (2021)

Favorable SSTR subtype selectivity of SiTATE: new momentum for clinical [(18)F]SiTATE PET
por: Wängler, Carmen, et al.
Publicado: (2022)

Towards Radiolabeled EGFR-Specific Peptides: Alternatives to GE11
por: Judmann, Benedikt, et al.
Publicado: (2023)

Synthesis of a Bifunctional Cross‐Bridged Chelating Agent, Peptide Conjugation, and Comparison of (68)Ga Labeling and Complex Stability Characteristics with Established Chelators
por: Damerow, Helen, et al.
Publicado: (2022)

Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy
por: Judmann, Benedikt, et al.
Publicado: (2020)

Good practices for the automated production of (18)F-SiFA radiopharmaceuticals
por: Blok, Simon, et al.
Publicado: (2023)

Side-by-Side Comparison of Five Chelators for (89)Zr-Labeling of Biomolecules: Investigation of Chemical/Radiochemical Properties and Complex Stability
por: Damerow, Helen, et al.
Publicado: (2021)

Synthesis, Radiolabeling, and In Vitro and In Vivo Characterization of Heterobivalent Peptidic Agents for Bispecific EGFR and Integrin α(v)β(3) Targeting
por: Braun, Diana, et al.
Publicado: (2023)

t-Bu(2)SiF-Derivatized D(2)-Receptor Ligands: The First SiFA-Containing Small Molecule Radiotracers for Target-Specific PET-Imaging
por: Iovkova-Berends, Ljuba, et al.
Publicado: (2011)

Design, Synthesis, In Vitro, and Initial In Vivo Evaluation of Heterobivalent Peptidic Ligands Targeting Both NPY(Y(1))- and GRP-Receptors—An Improvement for Breast Cancer Imaging?
por: Vall-Sagarra, Alicia, et al.
Publicado: (2018)

Toward Optimized (89)Zr-Immuno-PET: Side-by-Side Comparison of [(89)Zr]Zr-DFO-, [(89)Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [(89)Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
por: Damerow, Helen, et al.
Publicado: (2022)

Bimodal Imaging Probes for Combined PET and OI: Recent Developments and Future Directions for Hybrid Agent Development
por: Seibold, Uwe, et al.
Publicado: (2014)

Identification of a Suitable Peptidic Molecular Platform for the Development of NPY(Y(1))R‐Specific Imaging Agents
por: Krieger, Korbinian, et al.
Publicado: (2020)

(89)Zr, a Radiometal Nuclide with High Potential for Molecular Imaging with PET: Chemistry, Applications and Remaining Challenges
por: Fischer, Gabriel, et al.
Publicado: (2013)

iEDDA Conjugation Reaction in Radiometal Labeling of Peptides with (68)Ga and (64)Cu: Unexpected Findings
por: Litau, Shanna, et al.
Publicado: (2018)

Recent Advances in the Clinical Translation of Silicon Fluoride Acceptor (SiFA) (18)F-Radiopharmaceuticals
por: Gower-Fry, Lexi, et al.
Publicado: (2021)

Hybrid Multimodal Imaging Synthons for Chemoselective and Efficient Biomolecule Modification with Chelator and Near-Infrared Fluorescent Cyanine Dye
por: Hübner, Ralph, et al.
Publicado: (2020)

On the Viability of Tadalafil-Based (18)F-Radiotracers for In Vivo Phosphodiesterase 5 (PDE5) PET Imaging
por: Bailey, Justin J., et al.
Publicado: (2021)

α(v)β(3)-Specific Gold Nanoparticles for Fluorescence Imaging of Tumor Angiogenesis
por: Pretze, Marc, et al.
Publicado: (2021)

Cholinergic Depletion in Alzheimer's Disease Shown by [(18)F]FEOBV Autoradiography
por: Parent, Maxime J., et al.
Publicado: (2013)

Concordance between in vivo and postmortem measurements of cholinergic denervation in rats using PET with [(18)F]FEOBV and choline acetyltransferase immunochemistry
por: Parent, Maxime J, et al.
Publicado: (2013)

Microfluidics: A Groundbreaking Technology for PET Tracer Production?
por: Rensch, Christian, et al.
Publicado: (2013)

Molecular imaging of cardiac CXCR4 expression in a mouse model of acute myocardial infarction using a novel (68)Ga-mCXCL12 PET tracer
por: Zacherl, Mathias Johannes, et al.
Publicado: (2020)

GMP-compliant production of [(68)Ga]Ga-NeoB for positron emission tomography imaging of patients with gastrointestinal stromal tumor
por: Pretze, Marc, et al.
Publicado: (2021)

Dosimetry and optimal scan time of [(18)F]SiTATE-PET/CT in patients with neuroendocrine tumours
por: Beyer, Leonie, et al.
Publicado: (2021)

Correction to: Next‑generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR‑targeting peptide [(18)F]SiTATE
por: Unterrainer, Marcus, et al.
Publicado: (2023)

Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [(18)F]SiTATE
por: Unterrainer, Marcus, et al.
Publicado: (2023)

The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII
por: Farina, Antonietta Rosella, et al.
Publicado: (2018)

Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer
por: Wong, Derek, et al.
Publicado: (2019)

Functional Hybrid Molecules for the Visualization of Cancer: PESIN‐Homodimers Combined with Multimodal Molecular Imaging Probes for Positron Emission Tomography and Optical Imaging: Suited for Tracking of GRPR‐Positive Malignant Tissue
por: Hübner, Ralph, et al.
Publicado: (2020)

PESIN Conjugates for Multimodal Imaging: Can Multimerization Compensate Charge Influences on Cell Binding Properties? A Case Study †
por: Hübner, Ralph, et al.
Publicado: (2021)

Somatic rearrangement of the tropomyosin-receptor-kinase (trk) oncogene is rare in gastrointestinal cancer.
por: Fey, M. F., et al.
Publicado: (1988)

Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
por: Amatu, A, et al.
Publicado: (2019)

Toward in vivo proof of binding of (18)F-labeled inhibitor [(18)F]TRACK to peripheral tropomyosin receptor kinases
por: Wuest, Melinda, et al.
Publicado: (2022)

Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging
por: Bernard-Gauthier, Vadim, et al.
Publicado: (2015)

Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers
por: Jiang, Tingting, et al.
Publicado: (2021)

Tropomyosin receptor kinase B (TrkB) signalling: targeted therapy in neurogenic tumours
por: Li, Yuehua, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vllokrk98rdskngg9e5s4qv2js